Core Viewpoint - The controlling shareholder, Renhe (Group) Development Co., Ltd., plans to reduce its stake in Renhe Pharmaceutical Co., Ltd. due to its own development needs, intending to sell up to 3,000,000 shares, which represents 0.2143% of the company's total share capital [2][5]. Shareholder Holding Situation - As of the announcement date, Renhe (Group) Development Co., Ltd. holds 325,299,386 shares of the company, accounting for 23.2367% of the total shares [2]. Reduction Plan Details - The reduction plan will be executed within three months starting from 15 trading days after the announcement date, through centralized bidding or block trading methods [2][3]. - The number of shares to be reduced will be adjusted if there are changes in the company's capital structure, such as stock dividends or capital increases, but the proportion of the total share capital will remain unchanged [2][4]. Compliance and Commitments - Renhe (Group) Development Co., Ltd. has fulfilled its previous commitments regarding share trading restrictions, which were in place for 36 months after the shares became tradable [4][5]. - The current reduction plan does not conflict with any previously disclosed intentions or commitments [5].

Core Points - Renhe Pharmaceutical announced a share reduction plan involving its major shareholder, Renhe (Group) Development Co., Ltd., which currently holds 325,299,386 shares, accounting for 23.2367% of the total shares [2] - The company plans to reduce its holdings by up to 3,000,000 shares, representing a maximum of 0.2143% of the total share capital, within three months starting from 15 trading days after the announcement [2] - Any adjustments to the number of shares to be reduced will be made in the event of corporate actions such as stock dividends, capital increases, or new share issuances, but the percentage of total share capital will remain unchanged [2]

Core Viewpoint - Renhe Pharmaceutical (000650.SZ) announced that its controlling shareholder, Renhe (Group) Development Co., Ltd., plans to reduce its shareholding by up to 3 million shares within three months after the announcement, representing a maximum reduction of 0.2143% of the company's total share capital [1] Summary by Sections - Shareholding Reduction Plan - The controlling shareholder intends to reduce its stake through centralized bidding or block trading [1] - The maximum number of shares to be sold is 3 million [1] - The reduction will occur within three months following the announcement, starting 15 trading days after the disclosure [1]

Group 1 - The core point of the article is that Renhe Pharmaceutical announced a share reduction plan by its controlling shareholder, Renhe Group, intending to reduce up to 3 million shares, which is 0.2143% of the total share capital [1] - The share reduction will take place within three months after a 15 trading day period from the announcement date, using centralized bidding or block trading methods [1] - Any corporate actions such as stock dividends, capital increases, or new share issuances during the reduction period will lead to an adjustment in the number of shares to be reduced, but the percentage of total share capital will remain unchanged [1] Group 2 - For the first half of 2025, Renhe Pharmaceutical's revenue composition shows that 99.25% comes from the pharmaceutical industry, while other businesses account for 0.75% [1] - As of the report date, Renhe Pharmaceutical has a market capitalization of 8.9 billion yuan [1]

Core Viewpoint - Renhe Pharmaceutical (000650.SZ) announced a plan for its parent company, Renhe (Group) Development Co., Ltd., to reduce its shareholding by up to 3,000,000 shares, representing a maximum of 0.2143% of the total share capital within three months after the announcement [1] Summary by Sections - **Share Reduction Plan** - The reduction will be executed through centralized bidding or block trading [1] - The plan will be implemented within three months from the announcement date, starting 15 trading days after the disclosure [1] - **Adjustment Clause** - If any corporate actions such as stock dividends, capital increases, new share issuance, or rights issues occur during the reduction period, the number of shares to be reduced will be adjusted accordingly, while maintaining the same percentage of total share capital [1]

Core Viewpoint - Renhe Pharmaceutical (000650.SZ) announced a plan for its parent company, Renhe (Group) Development Co., Ltd., to reduce its shareholding by up to 3,000,000 shares, representing a maximum of 0.2143% of the total share capital within three months from the announcement date [1] Summary by Sections - **Share Reduction Plan** - The reduction will be executed through centralized bidding or block trading methods [1] - The adjustment of the reduction quantity will occur if there are corporate actions such as stock dividends, capital increases, or new share issuances during the reduction period, but the percentage of total share capital will remain unchanged [1]

证券代码：000650 证券简称：仁和药业 公告编号：2025-043 仁和药业股份有限公司 关于控股股东减持股份预披露的公告 控股股东仁和(集团)发展有限公司向本公司提供的信息内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ●股东持股的基本情况: 截至本公告披露日，仁和(集团)发展有限公司持有公司无限 售条件流通股 325,299,386 股，占公司股份总数的 23.2367%。 ●减持计划的主要内容：仁和(集团)发展有限公司因自身发展需要，拟自本公告披露 之日起 15 个交易日后的 3 个月内，通过集中竞价或大宗交易的方式减持公司股份不超过 3,000,000 股，减持比例不超过公司总股本的 0.2143%。减持计划实施期间，公司若发生送 红股、转增股本、增发新股或配股等股本除权事项的，减持数量将进行相应调整，但减持 股份占公司总股本的比例不变。 仁和药业股份有限公司（以下简称"公司"）于近日收到控股股东仁和（集 团）发展有限公司（以下简称"仁和集团"）出具的《股份减持计划告知函》， 现将有关情况公告如下： ...

人民财讯11月13日电，仁和药业（000650）11月13日公告，公司控股股东仁和(集团)发展有限公司因自 身发展需要，拟通过集中竞价或大宗交易的方式，减持公司股份不超过300万股，减持比例不超过公司 总股本的0.21%。 ...

仁和药业公告，截至公告披露日，控股股东仁和(集团)发展有限公司持有公司3.25亿股，占23.2367%； 因自身发展需要，拟自本公告披露之日起15个交易日后的3个月内，通过集中竞价或大宗交易方式减持 不超过300万股，减持比例不超过0.2143%；若减持期间公司发生送红股、转增股本、增发新股或配股 等事项，减持数量将相应调整，但减持股份占公司总股本的比例保持不变。 ...

Group 1 - The stock price of Renhe Pharmaceutical (000650) closed at 6.26 yuan on November 6, 2025, with no change in price, a turnover rate of 0.98%, a trading volume of 130,100 shares, and a transaction amount of 81.26 million yuan [1] - The company's classic formula, Er Dong Tang granules, did not participate in this year's medical insurance negotiations, as confirmed by the company secretary [2] - On November 6, there was a net outflow of 4.07 million yuan from main funds, indicating a cautious attitude from major investors [2] Group 2 - On the same day, there was a net inflow of 1.18 million yuan from speculative funds and a net inflow of 2.89 million yuan from retail investors [2]